Actively Recruiting
Comparing Pregabalin Eye Drops TB0001 to Timolol for Adults with Glaucoma or High Eye Pressure A Randomized, Masked Study to Evaluate Safety and Eye Pressure Effects
Led by Tavo Biotherapeutics · Updated on 2026-11-03
96
Participants Needed
3
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new eye drop containing pregabalin TB0001 as a potential treatment for adults with primary open-angle glaucoma or ocular hypertension. The study aims to compare how well TB0001 lowers eye pressure to timolol, a commonly used glaucoma eye drop, while checking safety and tolerability. This is a phase 2a randomized trial to identify the best dose of TB0001 for future studies. Participants will be randomly assigned to receive one of three strengths of TB0001 0.9%, 1.2%, or 1.5% once daily in the morning along with a matching placebo drop in the evening, or timolol 0.5% eye drops twice daily morning and evening. The treatment period lasts 28 days with both active and placebo drops used to keep the study masked. This double-masked, double-dummy design ensures fair comparison among groups. During the study, participants will have their eye pressure measured at several time points including baseline and day 28 to assess changes. Eye health, side effects, and tolerability will be monitored throughout. Additional assessments occur on days 1, 3, 7, and 14. Researchers will track the proportion of participants achieving significant eye pressure reduction and record any adverse events. The total participation is about one month.
CONDITIONS
Brief Title
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Research Team
J
Joel Thompson
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here